These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 32525513)

  • 1. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
    Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
    JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
    JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
    Kim CG; Kim KH; Pyo KH; Xin CF; Hong MH; Ahn BC; Kim Y; Choi SJ; Yoon HI; Lee JG; Lee CY; Park SY; Park SH; Cho BC; Shim HS; Shin EC; Kim HR
    Ann Oncol; 2019 Jul; 30(7):1104-1113. PubMed ID: 30977778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.
    Wang M; Huang H; Xu Z; Li Z; Shen L; Yu Y; Lu S
    Lung Cancer; 2022 Nov; 173():28-34. PubMed ID: 36116167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
    Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
    Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
    Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
    Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
    Lo Russo G; Facchinetti F; Tiseo M; Garassino MC; Ferrara R
    Curr Oncol Rep; 2020 Apr; 22(5):41. PubMed ID: 32296957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of
    Castello A; Rossi S; Mazziotti E; Toschi L; Lopci E
    J Nucl Med; 2020 Jun; 61(6):821-826. PubMed ID: 31862803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.
    Abbar B; De Castelbajac V; Gougis P; Assoun S; Pluvy J; Tesmoingt C; Théou-Anton N; Cazes A; Namour C; Khalil A; Gounant V; Besse B; Zalcman G; Brosseau S
    Lung Cancer; 2021 Feb; 152():109-118. PubMed ID: 33385736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Park HJ; Kim KW; Won SE; Yoon S; Chae YK; Tirumani SH; Ramaiya NH
    JAMA Netw Open; 2021 Mar; 4(3):e211136. PubMed ID: 33760090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
    Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
    Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting.
    Kanjanapan Y; Guduguntla G; Varikara AK; Szajer J; Yip D; Cockburn J; Fadia M
    Technol Cancer Res Treat; 2023; 22():15330338231209129. PubMed ID: 37885403
    [No Abstract]   [Full Text] [Related]  

  • 15. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.
    Djunadi TA; Oh Y; Lee J; Yu J; Chung LI; Lee Y; Kim L; Hong T; Lee S; Shah Z; Park JH; Yoon SM; Chae YK
    Clin Lung Cancer; 2024 Jun; 25(4):365-375.e14. PubMed ID: 38644088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
    Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
    Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
    Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
    Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy.
    Matsuo N; Azuma K; Kojima T; Ishii H; Tokito T; Yamada K; Hoshino T
    Invest New Drugs; 2021 Aug; 39(4):1150-1158. PubMed ID: 33483882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.